Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Enliven Therapeutics (Nasdaq: ELVN) announced on December 11, 2025 an inducement stock option grant tied to the start of Richard Fair's employment as President and Chief Executive Officer.

Rhea-AI Summary

Enliven Therapeutics (Nasdaq: ELVN) announced on December 11, 2025 an inducement stock option grant tied to the start of Richard Fair's employment as President and Chief Executive Officer.

The company granted an option to purchase 875,000 shares at an exercise price of $18.77 per share (equal to the closing price on the grant date). Vesting is 25% after one year (December 11, 2026) and then 1/48th monthly thereafter, subject to continued service. The award is under the 2025 Inducement Equity Incentive Plan and was granted pursuant to Nasdaq Listing Rule 5635(c)(4).

Positive

• 875,000-option grant issued to CEO Richard Fair on Dec 11, 2025
• Exercise price set at $18.77, equal to Dec 11, 2025 closing price

Negative

• Large option award creates potential shareholder dilution from 875,000 shares

Argus Dec 12 session

-10.18% close to close Open Argus

Details

News Market Reaction – ELVN

In the Dec 12 session, ELVN declined 10.18%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.2% in the session following this news. A negative reaction despite this govern...

Analysis

The stock dropped -10.2% in the session following this news. A negative reaction despite this governance-focused news would contrast with earlier gains seen after positive earnings and pipeline updates, such as the 3.36% rise on the Q3 2025 release. The current item is an 875,000-share inducement option at $18.77 for the CEO under Nasdaq rules, not a clinical or financial setback. Any downside move would be interpreted alongside recent insider selling activity disclosed in multiple Form 4 filings.

Key Figures

Inducement option size: 875,000 shares Exercise price: $18.77 per share Cliff vesting: 25% after 1 year +3 more

Inducement option size

875,000 shares

Stock option grant to President & CEO on Dec 11, 2025

Exercise price

$18.77 per share

Equal to ELVN closing price on grant date

Cliff vesting

25% after 1 year

First tranche vests on one-year anniversary of Dec 11, 2025

Ongoing vesting

1/48th monthly

Remaining option vests in equal monthly installments

Nasdaq rule

Rule 5635(c)(4)

Inducement award permitted under Nasdaq Listing Rules

Equity plan

2025 Inducement Equity Incentive Plan

Governs CEO inducement stock option grant

Historical Context

5 past events · Latest: Nov 12

5 events

1. Nov 12

   Earnings & update

   24h Move

   +3.4%

   Q3 2025 results, ENABLE progress, strong cash runway into 2029.

2. Nov 12

   Correction notice

   24h Move

   +3.4%

   Corrected earnings release reiterating Q3 metrics and cash position.

3. Nov 03

   Clinical data update

   24h Move

   -14.6%

   Positive ENABLE Phase 1a/1b CML data preview for ASH 2025.

4. Aug 25

   Conference presentations

   24h Move

   +1.9%

   SOHO 2025 oral/poster presentations of ENABLE ELVN-001 data.

5. Aug 13

   Earnings & financing

   24h Move

   -1.1%

   Q2 2025 results, positive trial data and $230M public offering.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inducement stock option, exercise price, equity incentive plan, Nasdaq Listing Rule 5635(c)(4)

4 terms

inducement stock option financial

"Enliven granted an inducement stock option to purchase 875,000 shares"

An inducement stock option is a grant of the right to buy company shares given to a new or existing employee as a special hiring or retention incentive, similar to offering a signing bonus but paid in future stock. Investors care because these options can motivate managers to grow the business and align their interests with shareholders, while also increasing the total number of shares over time and potentially diluting existing ownership and earnings per share.

exercise price financial

"The inducement stock option has an exercise price of $18.77 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equity incentive plan financial

"subject to the terms of the Enliven Therapeutics, Inc. 2025 Inducement Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Nasdaq Listing Rule 5635(c)(4) regulatory

"granted as an inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that on December 11, 2025, Enliven granted an inducement stock option to purchase 875,000 shares of Enliven's common stock to Richard Fair, Enliven's President and Chief Executive Officer and member of the board of directors, in connection with the commencement of Richard Fair's employment. 

The inducement stock option has an exercise price of $18.77 per share, which is equal to the closing price of a share of Enliven's common stock on the grant date, and shall vest as follows: 25% of the shares subject to the inducement stock option shall vest on the one year anniversary of December 11, 2025, and an additional one forty-eighth (1/48th) of the shares subject to the inducement stock option shall vest monthly thereafter, subject to continued service through each vesting date.

The inducement award is subject to the terms of the Enliven Therapeutics, Inc. 2025 Inducement Equity Incentive Plan and related form of option agreement, and was granted as an inducement material to Mr. Fair to enter into employment with Enliven in accordance with Nasdaq Listing Rule 5635(c)(4).  

About Enliven Therapeutics

Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302639654.html

SOURCE Enliven Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option award did Enliven (ELVN) grant to new CEO Richard Fair on December 11, 2025?

Enliven granted an inducement option to purchase 875,000 shares with an exercise price of $18.77 per share.

How does the Enliven (ELVN) CEO option vesting schedule work for the December 11, 2025 grant?

Vesting is 25% on the one-year anniversary (Dec 11, 2026) and then 1/48th of the shares monthly thereafter, subject to continued service.

What is the exercise price of the Enliven (ELVN) inducement option granted December 11, 2025?

The exercise price is $18.77 per share, equal to the closing price on the grant date.

Under what plan was the Enliven (ELVN) inducement award granted on December 11, 2025?

The award was granted under the Enliven Therapeutics 2025 Inducement Equity Incentive Plan and related option agreement.

Why did Enliven (ELVN) grant the inducement option to Richard Fair on December 11, 2025?

The company granted the inducement award to facilitate Mr. Fair's commencement of employment, in accordance with Nasdaq Listing Rule 5635(c)(4).